Physician

Rajesh Boorgu, M.D.

According to 2025 Medicare claims, Rajesh Boorgu, M.D. (NPI: 1033117817) practices nephrology in the Florence-Muscle Shoals, AL market, with the plurality of this provider's patient population coming from Lauderdale, AL. This provider's primary affiliated billing organization is N RAO BOORGU MD PC (NPI: 1780641951; TIN: 630794660) and primary practice location at 35630-5707. Boorgu is affiliated with the Huntsville ACO (ACO ID: A3579), participating under the MSSP model.

Boorgu's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 593 traditional Medicare patients, billed 11,417 HCPCS/CPT codes, and received $306,825 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 2,769 prescription claims across 465 beneficiaries totaling $777,812 in drug costs, led by Xphozah (Tenapanor Hcl). DME data shows 30 claims. Open Payments data shows 35 records totaling $792. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $617,653 to $306,825. Concurrently, Part D prescription costs did not follow a clear longitudinal pattern. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $24,295 to $4,494.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,588	33,562	$617,653
2016	1,324	41,350	$591,101
2017	1,057	16,743	$488,571
2018	960	11,599	$478,234
2019	944	11,130	$506,789
2020	823	10,799	$465,224
2021	778	9,916	$426,868
2022	759	9,052	$394,506
2023	661	11,230	$382,498
2024	593	11,417	$306,825

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	744	5,791	$729,586
2016	735	5,754	$782,394
2017	628	5,242	$684,753
2018	578	4,343	$534,356
2019	525	3,831	$407,484
2020	524	3,964	$416,887
2021	530	3,482	$480,933
2022	508	3,304	$612,394
2023	479	3,117	$573,303
2024	465	2,769	$777,812

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	20	228	$14,991
2016	31	178	$7,312
2017	16	115	$3,056
2018	12	56	$1,402
2019	N/R	75	$8,257
2020	N/R	74	$7,374
2021	N/R	72	$5,761
2022	N/R	44	$3,443
2023	N/R	32	$755
2024	N/R	30	$682

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	224	255	$133
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	315	1,397	$59
80053	Blood test, comprehensive group of blood chemicals	161	358	$10
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	161	383	$8
84100	Phosphate level	160	354	$5

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xphozah	Tenapanor Hcl	78	2,730	$262,696
Jynarque	Tolvaptan	11	330	$224,345
Velphoro	Sucroferric Oxyhydroxide	14	615	$39,685
Farxiga	Dapagliflozin Propanediol	28	1,900	$34,452
Auryxia	Ferric Citrate	11	315	$28,945

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	19	$358
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	11	$324

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	35	$792	Vifor Pharma, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Rajesh Boorgu, M.D.?

Tedicare shows public-source Medicare data for Rajesh Boorgu, M.D. (NPI 1033117817), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Rajesh Boorgu, M.D. have ACO affiliation data?

Rajesh Boorgu, M.D. is shown with ACO affiliation data for Huntsville ACO (MSSP, ACO ID A3579).

What billing organization is linked to Rajesh Boorgu, M.D.?

Rajesh Boorgu, M.D. is linked to N RAO BOORGU MD PC (billing NPI 1780641951) in the available physician profile data.

Does Rajesh Boorgu, M.D. have Open Payments data?

Rajesh Boorgu, M.D. has 35 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.